EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee-February 2024-www.financetom.com

EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee

Nov 19, 2025 6:08 AM

08:29 AM EST, 11/19/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said Wednesday that an independent Data Safety Monitoring Committee has recommended that its ongoing pivotal phase 3 program evaluating Duravyu for the treatment of wet age-related macular degeneration continue as planned without any modifications to the protocol.

Topline data from the trials is expected starting in mid-2026, the company said.

Shares of EyePoint Pharmaceuticals ( EYPT ) were 3.9% higher in recent premarket trading.

Previous page： Draganfly Down 13% In US Premarket As Prices US$2 Million Registered Direct Offering Next page： Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Draganfly Down 13% In US Premarket As Prices US$2 Million Registered Direct Offering

Aug 20, 2024

08:50 AM EDT, 08/20/2024 (MT Newswires) -- Draganfly ( DPRO ) , a drone solutions, and systems developer, was at last look down 13% and nearer 52 week lows in US premarket trade on Tuesday as it entered into a securities purchase agreement with a single institutional investor to purchase near 16.7 million units priced at US$0.12 each to raise...

Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing

Aug 20, 2024

08:50 AM EDT, 08/20/2024 (MT Newswires) -- Michael Andrew Chambers, Director, on August 16, 2024, executed a purchase for 37,038 shares in Sarepta Therapeutics ( SRPT ) for $4,955,728. Following the Form 4 filing with the SEC, Chambers has control over a total of 292,311 shares of the company, with 8,277 shares held directly and 284,034 controlled indirectly. SEC Filing:...

Bio-Rad Laboratories Names Jon DiVincenzo COO

Aug 20, 2024

08:50 AM EDT, 08/20/2024 (MT Newswires) -- Bio-Rad Laboratories ( BIO/B ) said Tuesday that it has appointed Jon DiVincenzo as chief operating officer, effective Sept. 9, to succeed Andy Last, who is set to retire. Most recently, DiVincenzo was president of Central Laboratories and International at Labcorp Holdings (LH). Price: 328.49, Change: +2.16, Percent Change: +0.66 ...

Oroco Resource Details Economic Study for Santo Tomas Project in Mexico

Aug 20, 2024

08:51 AM EDT, 08/20/2024 (MT Newswires) -- Oroco Resource ( ORRCF ) on Tuesday released the results of a preliminary economic assessment on the North and South zones of its Santo Tomas porphyry copper project in Mexico. The study outlined a posttax net present value of US$1.48 billion based on an 8% discount rate, with a 22.2% internal rate of...